Unicycive to Present at Upcoming March Investor Conferences
Unicycive Therapeutics (Nasdaq: UNCY) has announced that Dr. Shalabh Gupta, CEO, will present at two investor conferences in March 2022. The first is the 34th Annual ROTH Conference from March 13-15, where Dr. Gupta will offer an online presentation and participate in one-on-one meetings. The second event is the Maxim Group 2nd Annual Virtual Growth Conference on March 28 at 1:00 pm Eastern Time, featuring a fireside chat format. Unicycive is focused on developing innovative therapies for kidney diseases, including its lead drug Renazorb.
- None.
- None.
LOS ALTOS, Calif., March 3, 2022 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer of Unicycive, will participate at two upcoming investor conferences in March.
Unicycive management will present at the following investor conferences:
Date/Time: | March 13-15, 2022 (Virtually and In-Person) |
Format: | On demand on-line presentation (available now) and 1x1 meetings |
Presenter: | Dr. Shalabh Gupta |
Webcast: |
Dr. Gupta's presentation at the ROTH conference will be archived in the Investor Relations section of the Company's website here.
To schedule a one-on-one meeting with Unicycive, please contact your ROTH representative. For questions or further information about Unicycive, please contact Anne Marie Fields of Stern IR at 212-362-1200 or submit your request to ir@unicycive.com.
Maxim Group 2nd Annual Virtual Growth Conference
Date/Time: | March 28, 2022 at 1:00 pm Eastern time |
Format: | Fireside Chat |
Moderator: | Jason McCarthy, Ph.D., Senior Biotechnology Analyst at Maxim Group |
Presenter: | Dr. Shalabh Gupta |
Webcast: |
To schedule a one-on-one meeting with Unicycive management, visit Virtual Growth Conference | M-Vest, where you can submit a request for a virtual meeting and where you can view an On-demand on-line corporate presentation delivered by Dr. Gupta.
About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury. For more information, please visit www.unicycive.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/unicycive-to-present-at-upcoming-march-investor-conferences-301494762.html
SOURCE Unicycive Therapeutics Inc.
FAQ
When is Unicycive presenting at the ROTH Conference?
What is the format of Dr. Gupta's presentation at the Maxim Group conference?
How can I access the presentation by Unicycive at the ROTH Conference?
What is Unicycive's lead drug for kidney disease?
